On Friday, Shares of NCR Corporation (NYSE:NCR), inclined 2.74% to $23.66, during its last trading session.
NCR Corporation, declared it will be one of the 14 founding partners of the Mercedes-Benz Stadium set to open in 2017. The agreement continues a multi-year relationship between NCR and AMB Sports & Entertainment (AMBSE), comprised of the Atlanta Falcons, Atlanta United and Mercedes-Benz Stadium. The agreement underscores the company’s investment in the Atlanta community, where NCR is headquartered.
“Through our partnership with AMBSE and the Arthur M. Blank Family Foundation, we are thrilled by the opportunity to expand our commitment to the citizens of Atlanta and play a role in transforming the local Westside neighborhood,” said Bill Nuti, CEO and chairman of NCR Corporation. “As a founding partner of the Mercedes-Benz Stadium, NCR looks forward to ongoing our partnership with the Atlanta Falcons and welcoming and partnering with Atlanta’s new Major League Soccer team, Atlanta United.”
NCR Corporation, a technology company, provides solutions and services that enable businesses to connect, interact, and transact with their customers worldwide. The company operates through four segments: Financial Services, Retail Solutions, Hospitality, and Emerging Industries.
At the end of Friday’s trade, Shares of EXACT Sciences Corporation (NASDAQ:EXAS), lost -0.49% to $18.12.
Exact Sciences Corp., declared that the Centers for Medicare and Medicaid Services (CMS) issued a preliminary determination maintaining the current reimbursement rate for Cologuard, the company’s non-invasive, stool DNA-based colon cancer screening test.
CMS considered reimbursement for a new CPT billing code for Cologuard (81528), in addition to a request for reconsideration of Cologuard’s current reimbursement rate. In its determination, CMS approved a crosswalk of the new CPT code for Cologuard to three existing codes, which yield a current reimbursement rate of $492.72. The new CPT code replaces the G code assigned to Cologuard as part of CMS’ national coverage determination from October, 2014.
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing non-invasive colorectal cancer screening products. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer.
Finally, Heron Therapeutics Inc (NASDAQ:HRTX), ended its last trade with 10.80% gain, and closed at $27.70.
Heron Therapeutics, declared that data from the accomplished Phase 3 MAGIC study of SUSTOL (granisetron) Injection, extended release, were presented by Ian Schnadig, M.D., Principal Investigator for the MAGIC trial, US Oncology Research, Compass Oncology, at the American Society of Clinical Oncology (ASCO) 2015 Breast Cancer Symposium in San Francisco, CA. These data were presented in an oral presentation and poster titled “Phase III Study of APF530 as compared to Ondansetron with a Neurokinin 1 Antagonist + Corticosteroid in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: MAGIC Trial.” SUSTOL is Heron’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). SUSTOL has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Heron Therapeutics represented its New Drug Application (NDA) for SUSTOL with the FDA in July 2015.
Highlights comprise:
- The MAGIC trial represents the first registrational Phase 3 efficacy trial in patients receiving HEC using a consensus guideline–recommended three-drug regimen in both arms.
- For the primary endpoint, the proportion of patients with delayed-phase complete response (CR) was significantly greater with the SUSTOL (64.7%) as compared to ondansetron regimen (56.6%), an absolute treatment difference of 8.0% (95% CI 1.7-14.4; p = 0.014), equating to a relative 14.2% CR rate improvement.
- Within the cisplatin stratum (≥50 mg/m2), delayed-phase CR was greater with the SUSTOL (65.3%) as compared to ondansetron regimen (54.7%), an absolute treatment difference of 10.6% (95% CI -1.4-22.7), equating to a relative 19.4% CR rate improvement.
- A significantly greater proportion of patients did not require rescue medication in the delayed phase with the SUSTOLas compared to ondansetron regimen (p = 0.013).
- Patient-stated satisfaction with nausea and vomiting control was significantly greater with the SUSTOLas compared to ondansetron regimen in the delayed phase (p = 0.040).
- Rates of no nausea were numerically higher in the SUSTOLas compared to ondansetron regimen in the delayed and overall phases and a post hoc analysis indicated SUSTOLwas associated with significantly less frequent nausea in the delayed (p = 0.032) and overall phases (p = 0.048).
- SUSTOL was generally well tolerated with no new safety signals identified.
Heron Therapeutics, Inc. is a biotechnology company. The Company uses its technology to develop products to address unmet medical needs. Its Biochronomer polymer-based drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.